Generic Lipitor party over but olmesartan solid for Daiichi Sankyo
This article was originally published in Scrip
Ranbaxy and its owner Daiichi Sankyo may have benefited handsomely from the 180-day first-to-file US exclusivity for the Indian firm's generic version of Lipitor (atorvastatin) when it was launched in December 2011, but the hangover is hitting with a vengeance this year.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.